Losing the ability to sense low blood sugars is one of the scariest things for those of us living with diabetes.
For one college student at Purdue University, that hypoglycemia unawareness led to an average of three ER visits a week (!) Even with a CGM, this young man diagnosed with type 1 at age 5 wasn’t able to avoid the insulin reactions because they came on too quickly. It got to the point where…
Sometimes, diabetes science confuses me.
Let’s take the news of an emerging class of diabetes drugs (type 2-focused) that apparently do something we’ve always thought was bad… but it’s actually not.
Sodium-glucose transporter (SGLT-2) inhibitors increase insulin production and effectiveness and stop the liver from producing too much glucose. Basically, they work by spilling glucose over into the urine which leads to less sugar in your bloodstream. The effect: lower BGs and A1Cs.
Sure, it…
When I heard that Lilly Diabetes was holding its first-ever Diabetes Blogger Summit, my initial thought was: “It’s about flippin’ time.”
I’m an active patient advocate and blogger who’s lived in Indianapolis for close to a decade and worked for about six years in downtown Indy, where Lilly is based, but haven’t once been able to get a clear read on what the company is doing to engage the diabetes patient community, either online or…
Since we tend to be pretty America-centric over here, we wanted to shine a spotlight on the annual conference for the European Association for the Study of Diabetes (EASD), which is Europe’s equivalent to the American Diabetes Association. EASD is a huge professional org for doctors, researchers, nurses, students, and so on, with 7,000 members — from 110 different countries!
In addition to the annual conference, the EASD also produces their own trade publication, Diabetologia,…
The world of type 2 diabetes drugs is wacky indeed. While Amylin’s long-acting version of Byetta — called Bydureon and predicted by many experts to become a blockbuster — is still held up at FDA, the agency approved a new oral drug earlier this month that is reportedly unremarkable except in the lawsuit it has spurred.
The drug is called linagliptin, brand name Tradjenta, a new oral DPP-4 inhibitor from Eli Lilly and Boehringer that…